Expression of Foxp3+regulatory T cells and programmed death receptor 1 in epithelial ovarian cancer and its clinicopathological significance / 中国医师进修杂志

ABSTRACT

Objective To discuss the expression of Foxp3+ regulatory T cells (Foxp3+ Tregs) and programmed death receptor 1 (PD1) in epithelial ovarian cancer tissues and its clinicopathological significance. Methods One hundred and twenty-nine patients with epithelial ovarian cancer were selected from June 2011 and June 2014. Immunohistochemical method was used to detect the expression of Foxp3+ Tregs and PD1 in the epithelial ovarian cancer tissue and the normal tissue adjacent to the carcinoma. The clinicopathological relationship between the expression of Foxp3+ Tregs and PD1 of epithelial ovarian cancer were analyzed. Results The positive expression rate of Foxp3+Tregs and PD1 in epithelial ovarian cancer was significantly higher than that of normal tissue adjacent to the carcinoma [71.32%(92/129) vs. 1.55%(2/129), 65.89%(85/129) vs. 3.10%(4/129)], the difference was statistically significant (P<0.05). The expression of Foxp3+Tregs and PD1 in epithelial ovarian cancer was related to lymph node metastasis, TNM staging, and degree of differentiation (P<0.05), it was not related to the age, the size of the tumor, and the pathological type of the patients (P > 0.05). During the follow-up period of 3 years, the survival rate of patients with expression of Foxp3+ Tregs was significantly lower than that of the negative expression 21.74%(20/92)vs.78.38%(29/37), the survival rate of patients with PD1 positive expression was significantly lower than that of the negative expression28.24% (24/85) vs.56.82%(25/44) , P < 0.05. There was a positive correlation between the expression of Foxp3+ Tregs and PD1 in epithelial ovarian cancer (P < 0.05). Conclusions The abnormal expression of Foxp3+Tregs and PD1 in epithelial ovarian cancer is related to the development of tumour, it can be used as an important biomarker to evaluate the pathological progress and prognosis of patients. It is worth for further clinical promotion.